Glenn Melnick, PhD

Glenn Melnick, PhD, is a world-renowned expert in health economics and finance. He joined the USC Price School of Public Policy faculty in 1996 and currently holds the Blue Cross of California Chair in Health Care Finance. Previously, he served as a faculty member of the UCLA School of Public Health, a consultant at RAND and an expert witness to the Federal Trade Commission. He has been published in the American Journal of Public Health, Health Affairs, Medical Care, the Journal of Health Politics, Policy and Law, Health Policy Reform: Competition and Controls, and the Journal of Ambulatory Care Management. He has been principal investigator for a number of funded projects in Jakarta, Indonesia, and in Taiwan.

Recent Work

Are “All or Nothing” Contracts by Hospital Systems Anti-Competitive?—Evidence from a Recent Antitrust Lawsuit

The study sheds light on how the adoption of “all-or-nothing” contracting by multi-hospital systems can eliminate competitive constraints, enabling them to command significantly higher prices.
Categorized in
- Research
- Journal Articles
Trauma Center Hospitals Charged Higher Prices For Some Nontrauma Care Than Non–Trauma Center Hospitals, 2012–18

Abstract Rising prices are a major cause of increased health care spending and health insurance premiums in the US. Hospital prices, specifically—for both inpatient and outpatient care—are the largest driver of rising health care spending in the commercial insurance market. As a result, policy makers and employers are increasingly interested in understanding the determinants of […]
Categorized in
- Research
- Journal Articles
Post-COVID Trends in Hospital Financial Performance: Updated Data from California Paint an Improved but Challenging Picture for Hospitals and Commercially Insured Patients

Total hospital volume has returned to pre-COVID levels, but with changes.
Categorized in
After Their Initial Diagnosis, Many Adult COVID-19 Patients Continue Seeking Medical Care for up to Six Months or More

Analyzing claims data, does COVID-19 related healthcare utilization persist in for 180 days or more, also known as long COVID, after their initial diagnosis?

By Glenn Melnick, PhD and June F. O’Leary, PhD
Categorized in
California Must Quickly Implement Policies for Tracking and Controlling Health Care Costs and Price Increases

To protect Californians from rising health care costs, the state needs to strengthen price transparency and price competition, according to Melnick.

By Glenn Melnick, PhD
Categorized in
- Articles
- Perspective

Glenn Melnick, PhD's contact information

Glenn Melnick, PhD's Bio

Recent Work

Are “All or Nothing” Contracts by Hospital Systems Anti-Competitive?—Evidence from a Recent Antitrust Lawsuit

Trauma Center Hospitals Charged Higher Prices For Some Nontrauma Care Than Non–Trauma Center Hospitals, 2012–18

Post-COVID Trends in Hospital Financial Performance: Updated Data from California Paint an Improved but Challenging Picture for Hospitals and Commercially Insured Patients

After Their Initial Diagnosis, Many Adult COVID-19 Patients Continue Seeking Medical Care for up to Six Months or More

California Must Quickly Implement Policies for Tracking and Controlling Health Care Costs and Price Increases